GeneMedi knowledge base of Coronavirus disease 2019 (COVID-19): A Collection of reviews, diagnosis protocols, and guidance

SOCAIL MEDIA

1. Introduction

COVID-19, a novel pathogenic coronavirus (2019-nCoV or SARS-CoV2) induced disease, emerged in China and spread globally rapidly.

GeneMedi produces kinds of recombinant 2019 nCoV(SARS2 coronavirus) antigens as shown below: Nucleocapsid(N protein), Spike(S protein), RBD, S1+S2 ECD, Envelope (E protein), 3C-like Proteinase. All the recombinant proteins of 2019 nCoV are suitable for in functional ELISA,lateral-flow tests, and other immunoassays.

GeneMedi has submitted a preprints review about COVID-19 and 2019-nCoV.

Click here for the full-text reading:
Viral vector-based vaccine; DNA-based vaccine; RNA based vaccine – A landscape for vaccine technology against infectious disease, COVID-19 and tumor.

An Insight of comparison between COVID-19 (2019-nCoV disease) and SARS in pathology and pathogenesis

Landscape Coronavirus Disease 2019 test (COVID-19 test) in vitro — A comparison of PCR vs Immunoassay vs Crispr-Based test

In the mission of helping global scientists for the development of diagnosis and drug against 2019 nCoV(SARS2 coronavirus), GeneMedi scientists will keep moving.

4. Landscape of vaccine development against COVID-19 (2019 nCoV, SARS2 coronavirus).

5. Research Guidance of COVID-19 (2019 nCoV, SARS2 coronavirus).